MDXG Q4 2024 Earnings — MiMedx Group, Inc. Revenue & Financial Results | Market Cap Arena

MDXGMiMedx Group, Inc.

$684M

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$93M+7.0% YoY

Gross Profit

$76M81.8% margin

Operating Income

$11M11.9% margin

Net Income

$7M8.0% margin

EPS (Diluted)

$0.05

QoQ Revenue Growth

+10.5%

Cash Flow

Operating Cash Flow

$19M

Free Cash Flow

$19M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$264M

Total Liabilities

$71M

Stockholders' Equity

$193M

Cash & Equivalents

$104M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$93M	$87M	+7.0%
Gross Profit	$76M	$73M	+4.1%
Operating Income	$11M	$15M	-28.6%
Net Income	$7M	$53M	-86.1%

Revenue Segments

Surgical

$32M100%